Sarah A. Reda

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d2a5b100-504e-11ef-931e-8373c6b518fb.jpg

First Name

Sarah

Last Name

Reda

NPI

1003304510

Faculty ID

17794

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

186405

Visit Type ID

2499

Is Open Scheduling

On

Sriram Machineni

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c68653a0-bec9-11ee-aa99-759018b444d6.jpg

First Name

Sriram

Last Name

Machineni

NPI

1750350666

Faculty ID

17510

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni obtained his medical degree from the All India Institute of Medical Sciences in New Delhi, followed by a residency in internal medicine at the State University of New York at &nbsp;Buffalo. He served as chief resident and primary care teaching physician at Buffalo General Hospital. He subsequently completed a clinical and research fellowship in obesity medicine and metabolism at Massachusetts General Hospital/ Harvard Medical School and stayed on as an instructor. Dr. Machineni studied energy balance and body fat regulation in animal models allowing the interpretation of clinical research findings and phenotypes in the context of physiology.&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">&nbsp;</p>
<p class="MsoNormal" style="margin: 0in; font-size: 12pt; font-family: Calibri, sans-serif;">Dr. Machineni moved to the University of North Carolina at Chapel Hill (UNC) to start a clinical obesity program for treatment, education, and pharmaceutical clinical obesity trials. During his term at UNC, he helped create an obesity primary care network in central North Carolina. He was recruited to Montefiore Medical Center to develop a new medical obesity program.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">The Fleischer Institute Medical Weight Center at Montefiore Einstein, founded by Dr. Machineni, is designed to support clinical, educational, and research endeavors in the field of obesity medicine. The program leverages individual variations in response to treatments and uses multiple modalities for weight reduction to treat the comorbidities of obesity and improve quality of life. Special programs are available for individuals who need to lose weight to quality for medical and surgical procedures. The Medical Weight Center works closely with the Montefiore bariatric surgery program to offer a broad spectrum of treatment modalities.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="font-family: Calibri, sans-serif;">Dr. Machineni has clinical expertise in the m</span><span style="font-family: Calibri, sans-serif; font-size: 12pt;">ultidisciplinary management of obesity, anti-obesity medications, and post-bariatric medical complications, including nutritional deficiencies, hypoglycemia, weight regain, malabsorption, and diarrhea. He</span><span style="font-family: Calibri, sans-serif;">&nbsp;is among a handful of physicians in the New York area with Castle Connolly Top Doctors designation in obesity medicine.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>1: Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H,Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM; <strong>SURMOUNT-2 investigators</strong>.Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi:10.1016/S0140-6736(23)01200-X. Epub ahead of print. PMID: 37385275.</p>
<p>2: Pagidipati NJ, Mulder H, Chiswell K, Lampron Z, Jones WS, <strong>Machineni S</strong>,Waitman LR, Mongraw-Chaffin M, Waterman F, Kumar N, Ramasamy A, Smolarz G,Peterson ED, O'Brien E. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity. PrevMed. 2023 May;170:107496. doi:10.1016/j.ypmed.2023.107496. Epub 2023 Mar 29.PMID: 36997096.</p>
<p>3: Ro SJ, Lackey AR, Aymes SE, McCauley JL, Davis TC, Wang R, Stanley W, Ratner SP, <strong>Machineni S</strong>, Fiscus LC. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System. Fam Med. 2023 Mar;55(3):189-194.doi: 10.22454/FamMed.2023.603918. Epub 2023 Jan 31. PMID: 36888674.</p>
<p>4: Aronne LJ, Bramblette S, Ingelfinger JR, Jastreboff AM, <strong>Machineni S,</strong> Massie N, Rosen CJ. When Weight Impacts Health. N Engl J Med. 2023 Jan 12;388(2):e2. doi: 10.1056/NEJMp2215794. PMID: 36630621.</p>
<p>5: Aronne LJ, Bramblette S, Huett-Garcia A, Ingelfinger JR, Jastreboff AM, <strong>Machineni S</strong>, Massie N, Rosen CJ. Weight and Health - Pathophysiology and&nbsp;Therapies. N Engl J Med. 2022 Dec 15;387(24):e62. doi: 10.1056/NEJMp2214423. PMID: 36516089.</p>
<p>6: le Roux CW, Zhang S, Aronne LJ, Kushner RF, Chao AM, <strong>Machineni S</strong>, Dunn J, Chigutsa FB, Ahmad NN, Bunck MC. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023 Jan;31(1):96-110. doi: 10.1002/oby.23612. Epub 2022 Dec 7. PMID: 36478180; PMCID: PMC10107501.</p>
<p>7: Bionic Pancreas Research Group; Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K,Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB,Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, <strong>Machineni S</strong>, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 Sep 29;387(13):1161-1172. doi: 10.1056/NEJMoa2205225. PMID: 36170500; PMCID: PMC10028490.</p>
<p>8: Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, <strong>Machineni S</strong>, Varbo A,Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism andGlycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg AmongParticipants With Prediabetes in the STEP Program. Diabetes Care. 2022 Oct1;45(10):2396-2405. doi: 10.2337/dc21-1785. PMID: 35724304; PMCID: PMC9862484.</p>
<p>9: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A,Zhang S, Liu B, Bunck MC, Stefanski A; <strong>SURMOUNT-1 Investigators</strong>. TirzepatideOnce Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.</p>
<p>10: Klein KR, Freeman JLR, Dunn I, Dvergsten C, Kirkman MS, Buse JB, Valcarce C;<strong>SimpliciT1 research group</strong>. The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes. Diabetes Care. 2021 Apr;44(4):960-968. doi:10.2337/dc20-2684. Epub 2021 Feb 23. PMID:33622669; PMCID: PMC7985421.</p>
<p>11: Melanie Davies, Louise F&aelig;rch, Ole K Jeppesen, Arash Pakseresht, Sue D Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A Wadden, Ildiko Lingvay; <strong>STEP 2 Study Group</strong>.&nbsp; Semaglutide 2&middot;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 Mar 13;397(10278):971-984. PMID: 33667417.</p>
<p>12: Rosman L, Armbruster T, Kyazimzade S, Tugaoen Z, Mazzella AJ, Deyo Z, Walker J, <strong>Machineni S,</strong> Gehi A. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19. Pacing Clin Electrophysiol. 2021 Mar;44(3):451-461. doi: 10.1111/pace.14188. Epub 2021 Feb 17. PMID: 33565642; PMCID: PMC8014277.</p>
<p>13: Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; <strong>STEP 3 Investigators.</strong> Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021 Feb 24. PMID: 33625476; PMCID: PMC7905697.</p>
<p>14: Jensen SM, Thompson RE, <strong>Machineni S,</strong> Overby DW, Farrell TM. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass. Am Surg. 2021 Apr;87(4):576-580. doi: 10.1177/0003134820952427. Epub 2020 Oct 30. PMID: 33125276.</p>
<p>&nbsp;</p>
<p>15: Kushner RF, Batsis JA, Butsch WS, Davis N, Golden A, Halperin F, Kidambi S, <strong>Machineni S,</strong> Novick M, Port A, Rubino DM, Saunders KH, Shapiro Manning L, Soleymani T, Kahan S. Weight History in Clinical Practice: The State of the Science and Future Directions. Obesity (Silver Spring). 2020 Jan;28(1):9-17. doi: 10.1002/oby.22642. PMID: 31858735.</p>
<p>16: Kushner RF, Butsch WS, Kahan S, <strong>Machineni S,</strong> Cook S, Aronne LJ. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested? Teach Learn Med. 2017 Apr-Jun;29(2):123-128. doi:10.1080/10401334.2016.1250641. Epub 2016 Dec 29. PMID: 28033472.</p>
<p>17: Carmody JS, Ahmad NN, <strong>Machineni S,</strong> Lajoie S, Kaplan LM. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice. Endocrinology. 2015 Sep;156(9):3183-91. doi: 10.1210/en.2015-1226. Epub 2015 Jun 11. PMID: 26066076; PMCID: PMC4541621.</p>
<p>18: Liou AP, Paziuk M, Luevano JM Jr, <strong>Machineni S,</strong> Turnbaugh PJ, Kaplan LM. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med. 2013 Mar 27;5(178):178ra41. doi:10.1126/scitranslmed.3005687. PMID: 23536013; PMCID: PMC3652229.</p>
<p>19: Bose M, Teixeira J, Olivan B, Bawa B, Arias S, <strong>Machineni S,</strong> Pi-Sunyer FX, Scherer PE, Laferr&egrave;re B. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010 Mar;2(1):47-55. doi: 10.1111/j.1753-0407.2009.00064.x. PMID: 20676394; PMCID: PMC2910618.</p>
<p>20: Bose M, <strong>Machineni S,</strong> Oliv&aacute;n B, Teixeira J, McGinty JJ, Bawa B, Koshy N, Colarusso A, Laferr&egrave;re B. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding. Obesity (Silver Spring). 2010 Jun;18(6):1085-91. doi: 10.1038/oby.2009.473. Epub 2010 Jan 7.PMID: 20057364; PMCID: PMC2877144.</p>

EMR ID

179058

Is Open Scheduling

Off

Mauricio Drummond, Jr.

https://assets.montefioreeinstein.org/profiles/images/Drummond_Jr_Mauricio_MD_2x.jpg

First Name

Mauricio

Last Name

Drummond, Jr.

NPI

1801450176

Faculty ID

17445

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Dr. Drummond&rsquo;s clinical focus is in pediatric sports medicine with a special focus on knee pathology.

Research Focus

Dr. Drummond&rsquo;s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears

Elsevier Profile

EMR ID

123889

Biography

<p>Mauricio Drummond Jr., MD, is an attending surgeon and Assistant Professor, Pediatrics and Orthopedic Surgery at Children&rsquo;s Hospital at Montefiore. Dr. Drummond&rsquo;s clinical focus is in pediatric sports medicine with a special focus on knee pathology. His interests include pediatric orthopedic surgery, complex pediatric and adolescent sports medicine, ACL, PCL and multiligament knee injuries, discoid meniscus, meniscus transplantation, patellofemoral instability, trochlear dysplasia, cartilage preservation and pediatric trauma and limb deformities.</p><p>In 1996, Dr. Drummond earned his Doctor of Medicine from Universidade Federal do Rio de Janeiro (Federal University of Rio de Janeiro) in Rio de Janeiro, Brazil. He completed his residency training at the same institution, and practiced as a knee specialist for more than 13 years in Brazil. In 2018, he came to the United States, completing an orthopedic surgery research fellowship at Cleveland Clinic Foundation in 2019 and an orthopedic sports medicine fellowship at the University of Pittsburgh Medical Center in 2020. He continued his postdoctoral training, completing his pediatric orthopedics and limb deformity fellowship at Montefiore Medical Center in 2021 and his pediatric orthopedics fellowship at Connecticut Children&rsquo;s Medical Center in 2022.</p><p>Dr. Drummond&rsquo;s research interests include discoid meniscus, trochlear dysplasia, patellofemoral instability and ACL tears. He has shared his work nationally and internationally through peer-reviewed journals and podium and poster presentations. He is also a reviewer for the <em>American Journal of Sports Medicine</em>.</p><p>Dr. Drummond is a member of several professional organizations including the International Society of Arthroscopy and Knee Orthopaedic Sports Medicine (ISAKOS), the American Orthopaedic Society for Sports Medicine (AOSSM), the Pediatric Orthopaedic Society of North America (POSNA) and the Pediatric Research in Sports Medicine Society (PRiSM).</p>

Is Open Scheduling

Off

Shiu M. Young

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shiu

Last Name

Young

NPI

1467742726

Faculty ID

14110

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5826

Is Open Scheduling

Off

Rui Yang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Yang_Rui_MD_420x504.jpg

First Name

Rui

Last Name

Yang

NPI

1215280532

Faculty ID

9892

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopaedic residency at Peking University People&rsquo;s Hospital in Beijing, China.&nbsp; Following his training in China, he came to the United States where he earned a Master&rsquo;s degree in Biological Sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopaedic surgery residency at the University of Texas, in Houston and then he did a fellowship in Orthopaedic Oncology at Memorial Sloan-Kettering Cancer Center.</p>
<p>Dr. Yang specializes in the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system. A multidisciplinary approach is emphasized in his practice. He performs surgery to remove the tumor fom the limb and pelvis, and rebuild them using techniques tailored for each individual patient. Dr. Yang is also interested in treating metastatic bony lesions originating from other parts of the body.</p>
<p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumorigenesis of osteosarcoma and the genetic profile of the tumors as comparison to its normal counterpart tissues.&nbsp; He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, as well as novel strategies to overcome it in collaboration with the pediatric sarcoma teams.</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p>1. Peer-reviewed Papers</p>
<p>1) <strong>Yang, R.</strong>, Piperdi, S.,&nbsp; Zhang, Y., Neophytou, N., Zhu, W., Hoang, B.H., Mason, G., Geller, D., Dorfman, H,, Healey, J.H., Phinney, D.G., and Gorlick, R. Transcriptional Profiling Identifies the Signaling Axes of the Insulin Growth Factor and the Transforming Growth Factor-beta as involved in the Pathogenesis of Osteosarcoma. Clin Orthop Relat Res. 2015. PMID: 26463566</p>
<p>2) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.,</strong> Linkov, I., Sowers, R., DiResta, G.R., Gorlick, R., Healey, J.H.&nbsp;Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma <a href="http://www.ncbi.nlm.nih.gov/pubmed/20052438">.</a&gt; Ann Acad Med Singapore. 2009; 38(12):1041-7. PMID: 20052438</p>
<p>3) Li, N., <strong>Yang, R.</strong>, Zhang, W., Dorfman, H., Rao, P., and Gorlick, R. Genetically Transforming Human Mesenchymal Stem Cells to Sarcomas: changes in cellular phenotype and multilineage differentiation potential. Cancer. 2009; 115(20): 4795-806. PMID: 19593798</p>
<p>4) <strong>Yang, R</strong>., Piperdi, S., and Gorlick, R. Activation of the RAF/MEK/ERK pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res. 2008;14(20): 6396-404. PMID: 18927278</p>
<p>5) <strong>Yang, R.</strong>, Qin, J., Hoang, B.H., Healey, J.H., and Gorlick, R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma. Clin Orthop Relat Res 2008;466:2046-51. PMID: 18528741</p>
<p>6) Nathan, S.S., Huvos, A.G., Casas-Ganem, J.E., <strong>Yang, R.</strong>, Linkov, I., Sowers, R., Diresta, G.R., Gorlick, R., and Healey, J.H. Tumor interstitial fluid pressure may regulate angiogenic factors in osteosarcoma. J Orthop Res 2008;26:1-6. PMID: 18473395</p>
<p>7) <strong>Yang, R.</strong>, Li, W.W., Hoang, B.H., Kim, H., Banerjee, D., Kheradpour, A., Healey, J.H., Meyers, P.A., Bertino, J.R., and Gorlick, R. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer 2008;8:124. PMID: 18452618</p>
<p>8) <strong>Yang, R.</strong>, Kolb, E.A., Qin, J., Chou, A., Sowers, R., Hoang, B., Healey, J.H., Huvos, A.G., Meyers, P.A. and Gorlick, R. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate. Clin Cancer Res 2007;13:2557-67. PMID: 17473184</p>
<p>9) <strong>Yang, R.</strong>, Hoang, B.H., Kubo, T., Kawano, H., Chou, A., Sowers, R., Huvos, A.G., Meyers, P.A., Healey, J.H. and Gorlick, R. Over-expression of parathyroid hormone Type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 2007;121:943-54. PMID: 17410535</p>
<p>10) Laverdiere, C., Hoang, B.H., <strong>Yang, R.</strong>, Sowers, R., Qin, J., Meyers, P.A., Huvos, A.G., Healey, J.H. and Gorlick, R. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res 2005;11:2561-7. PMID: 15814634</p>
<p>11) Nathan, S.S., DiResta, G.R., Casas-Ganem, J.E., Hoang, B.H., Sowers, R., <strong>Yang, R.</strong>, Huvos, A.G., Gorlick, R. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma. Clin Cancer Res 2005;11:2389-97. PMID: 15788690</p>
<p>12) Flintoff, W.F., Sadlish, H., Gorlick, R., <strong>Yang, R.</strong>, Williams, F.M. Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas. Biochim Biophys Acta 2004;1690:110-7. PMID: 15469899</p>
<p>13) Hoang, B.H., Kubo, T., Healey, J.H., <strong>Yang, R.</strong>, Nathan, S.S., Kolb, E.A., Mazza, B., Meyers, P.A. and Gorlick, R. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64:2734-9. PMID: 15087387</p>
<p>14) Hoang, B.H., Kubo, T., Healey, J.H., Sowers, R., Mazza, B., <strong>Yang, R.</strong>, Huvos, A.G., Meyers, P.A. and Gorlick, R. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-11. PMID: 14735475</p>
<p>15) <strong>Yang, R.</strong>, Sowers, R., Mazza, B., Healey, J.H., Huvos, A., Grier, H., Bernstein, M., Beardsley, G.P., Krailo, M.D., Devidas, M., Bertino, J.R., Meyers, P.A. and Gorlick, R. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res 2003;9:837-44. PMID: 12576457</p>
<p>&nbsp;</p>
<p>2. Book Chapters</p>
<p align="left">1) Orthopedic Oncology. Editor: Xun, W.P., Feng, C.H. People&rsquo;s Military Medical Publisher.</p>
<p>(ISBN: 7-80157-159-2), 2001.</p>
<p>2) Review of Surgery: A Guiding Book for Medical Students. Section of Orthopedics. Editor: Jiang, B.G. Beijing Medical University Publisher.&nbsp; (ISBN: 7-81034-946-5), 1999.</p>

EMR ID

78569

Biography

<p>Dr. Yang is a fellowship-trained orthopedic surgeon recognized for his multidisciplinary approach to the diagnosis and treatment of benign and malignant tumors in the musculoskeletal system, including metastatic bony lesions as well as primary tumors. He also serves as an Assistant Professor at our Albert Einstein College of Medicine.</p><p>Dr. Yang earned his medical degree at Beijing Medical University in China followed by an orthopedic residency at Peking University People?s Hospital in Beijing, China. Following his training in China, he came to the United States where he earned a master?s degree in biological sciences from Hunter College at the City University of New York. Dr. Yang completed a second orthopedic surgery residency at the University of Texas, in Houston, followed by a fellowship in orthopedic oncology at Memorial Sloan-Kettering Cancer Center.</p><p>Dr. Yang has a strong interest in the research of musculoskeletal tumors. He has been studying the tumor genesis of osteosarcoma and the genetic profile of the tumors as compared to normal counterpart tissues. He has also studied the mechanism of chemotherapy resistance in osteosarcoma and related signaling pathways, in addition to novel strategies to overcome it in collaboration with pediatric sarcoma teams.</p>

Is Open Scheduling

Off

Beatrice Y. Wong

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4012680-c3c5-11eb-9ea2-7374238588d1.jpg

First Name

Beatrice

Last Name

Wong

NPI

1033656541

Faculty ID

16257

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

95560

Visit Type ID

2499

Is Open Scheduling

On

Lucia R. Wolgast

https://assets.montefioreeinstein.org/profiles/images/Wolgast_Lucia_MD_2x.jpg

First Name

Lucia

Last Name

Wolgast

NPI

1770881260

Faculty ID

12874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Hematology and Coagulation<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Antiphospholipid Syndrome<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

4811

Is Open Scheduling

Off

Shudan Wang

https://assets.montefioreeinstein.org/profiles/images/physphoto/Wang_Shudan_420x504.jpg

First Name

Shudan

Last Name

Wang

NPI

1831432780

Faculty ID

15876

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang is an Attending Physician in the Division of Rheumatology at Montefiore Medical Center, and an Assistant Professor of Medicine at Albert Einstein College of Medicine. She is board certified in both internal medicine and rheumatology and currently sees patients at the Montefiore Westchester Practice at Taxter Road. Dr. Wang has an expertise in lupus and lupus related kidney disease. She is also skilled to see a wide range of other rheumatologic diseases, including but not limited to antiphospholipid syndrome, Sjogren&rsquo;s syndrome, rheumatoid arthritis, <span style="color: black;">spondyloarthropathy</span>&nbsp;and psoriatic arthritis, vasculitis, myositis, polymyalgia rheumatica, scleroderma and osteoarthritis.</span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang graduated from McGill University with a major in Physiology and Statistics in 2009. Dr. Wang received her medical degree from Rutgers New Jersey Medical School in 2013. She subsequently completed her internal medicine residency training at New York Presbyterian Hospital Cornell in 2016, followed by a fellowship in Rheumatology at New York University Hospital in 2018. Dr. Wang obtained a MS in clinical research from the Albert Einstein Clinical Research Training Program in 2021. </span></p>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; text-indent: .5in; line-height: normal;"><span style="font-size: 12.0pt; font-family: 'Arial',sans-serif; mso-fareast-font-family: 'Times New Roman';">Dr. Wang's research interest is in lupus, focused on the role of the complement system in lupus related kidney disease. Dr. Wang is supported by the NIH KL2 Mentored Clinical Research Scholar Grant and the Rheumatology Research Foundation K-Bridge Grant to investigate complement biomarkers in lupus nephritis using various translational approaches including immunohistochemistry, urine proteomics and single cell RNA sequencing. Dr. Wang has experience working with large cohorts and databases, recruiting patients for the Einstein Rheumatic Disease Registry and serve as sub-investigator for lupus clinical trials. She has published first author papers in prestigious journals, presented her academic work at national meetings and served on NIH and CDC study sections. She was recognized by American College of Rheumatology as a Distinguished Fellow nationally for translational research and clinical excellence in 2018.</span></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="mso-outline-level: 1;"><strong><span style="font-family: 'Arial',sans-serif;">Wang Shudan</span></strong><span style="font-family: 'Arial',sans-serif;">, Wu M, Chiriboga L, Zeck B, Goilav B, Wang Shuwei, Jimenez-Londono A, </span><span style="font-family: 'Arial',sans-serif;">Putterman C, Schwartz D, Pullman J, Broder A, HM Belmont. Membrane Attack Complex (MAC) Deposition in Renal Tubules is Associated with Interstitial Fibrosis/Tubular Atrophy: A Pilot Study. <em>Lupus Science &amp; Medicine. </em>2022 Jan; 9(1). </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Tagoe, CE, Wang W, <strong>Wang S</strong>, Barbour K. Association of anti-thyroid antibodies with radiographic knee osteoarthritis and chondrocalcinosis: a NHANES III study. <em>Therapeutic Advances in Musculoskeletal Disease. </em>2021 Aug 4; 13. </span></p>
<p class="MsoNormal" style="mso-outline-level: 1;"><span style="font-family: 'Arial',sans-serif;">Guerrero, MS, Londono, A, Dobrowolski C, Mowrey WB, Goilav B, <strong>Wang S</strong>, Broder A. Systemic Lupus Erythematosus Activity and Hydroxychloroquine Use Before and After End-Stage Renal Disease. <em>BMC Nephrology</em>. 2020 Oct 28; 21(1): 450.</span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif;">Wu M, Pillinger MH, Krasnokutsky, S, and Barbour K. The Association between Asymptomatic Hyperuricemia and Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey. <a title="Osteoarthritis and cartilage." href="https://www.ncbi.nlm.nih.gov/pubmed/?term=The+Association+between+Asymp… class="highlight"><em><span style="color: windowtext; text-decoration: none; text-underline: none;">Osteoarthritis</span></em></span><em> Cartilage.</em></a> 2019 Sep;27(9):1301-1308. </span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Wu M, Chiriboga L, Zeck B, HM Belmont. Membrane Attack Complex (MAC) Deposition in Lupus Nephritis is Associated with Hypertension and Poor Clinical Response to Treatment. <em style="mso-bidi-font-style: normal;">Semin Arthritis Rheum. 2018; 48(2): 256-262.</em><span style="mso-spacerun: yes;">&nbsp; </span></span></p>
<p class="MsoNormal"><strong style="mso-bidi-font-weight: normal;"><span style="font-family: 'Arial',sans-serif; color: black;">Wang S, </span></strong><span style="font-family: 'Arial',sans-serif; color: black;">Broder N, Marchetta P, Nowatzky J. Myelodysplastic syndrome presenting as a Behcet&rsquo;s like syndrome with aortitis. <em style="mso-bidi-font-style: normal;">BMJ Case Rep. 2018 March 15. </em><span style="mso-spacerun: yes;">&nbsp;</span></span></p>
<p class="MsoNormal"><span style="font-family: 'Arial',sans-serif; color: black;">Oshima-Takane Y, <strong style="mso-bidi-font-weight: normal;">Wang S</strong>, Takane M and Takane, Y. T</span><span style="font-family: 'Arial',sans-serif;">he Acquisition of Personal Pronouns in English: Neural Network Stimulations. S<em style="mso-bidi-font-style: normal;">tudies in Language Sciences. 2014, Jan: 13 (53-69).</em></span></p>
<p class="MsoNormal" style="margin-right: 24.0pt;"><span style="font-family: 'Arial',sans-serif;">Sleat DE, Ding L, <strong style="mso-bidi-font-weight: normal;">Wang S, </strong>Zhao C, Wang Y, Zheng H, Moore DF, Sims KB, Lobel P<strong style="mso-bidi-font-weight: normal;">. </strong>Mass spectrometry-based protein profiling to determine the cause of lysosomal storage disease of unknown etiology. <em style="mso-bidi-font-style: normal;">Mole Cell Proteomics</em>. <em style="mso-bidi-font-style: normal;">2009 Jul; 8(7): 1708-18.</em> </span></p>
<p class="MsoNormal" style="margin-right: 24.0pt; text-indent: -.25in;"><strong style="mso-bidi-font-weight: normal;"><span style="mso-bidi-font-family: Arial;">&nbsp;</span></strong></p>

EMR ID

13915

Visit Type ID

2528

Is Open Scheduling

On

Zocdoc Link

Esperanza Villanueva-Siles

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/83dd1f30-84f7-11ef-b387-d348df9d586b.jpg

First Name

Esperanza

Last Name

Villanueva-Siles

NPI

1518047018

Faculty ID

10058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4730

Is Open Scheduling

Off

Ana Y. Valdivia

https://assets.montefioreeinstein.org/profiles/images/physphoto/Valdivia_Ana_MD_420x504.jpg

First Name

Ana

Last Name

Valdivia

NPI

1184728404

Faculty ID

8283

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4272

Biography

<p>Ana Y. Valdivia, MD, is an attending physician at Montefiore Einstein and Assistant Professor, Diagnostic Radiology at our Albert Einstein College of Medicine. Dr. Valdivia&rsquo;s clinical focus involves all aspects of nuclear medicine, with a particular focus on positron emission tomography&ndash;computed tomography (PET-CT).</p><p>After receiving her Bachelor of Science in chemistry at the University of Puerto Rico in 1990, Dr. Valdivia attended Universidad Central del Caribe School of Medicine, earning her Doctor of Medicine in 1994. She completed her internal medicine residency at Veterans Affairs Medical Center in 1997, followed by her nuclear medicine residency at Mount Sinai Medical Center in 1999.</p><p>Dr. Valdivia&rsquo;s research involves PET-CT, frequently focusing on brain imaging. She has shared her research through peer-reviewed journals, book chapters, abstracts, exhibits, and oral and poster presentations. She is also an invited reviewer for the International Journal of Surgery.</p><p>Dr. Valdivia is board certified by the American Board of Internal Medicine and the American Board of Nuclear Medicine. She is a member of the Society of Nuclear Medicine and the American College of Radiology.</p>

Is Open Scheduling

Off